Clinical Trials Browser

Phase 2/3 × Carcinoma, Merkel Cell × 90 days × Clear all

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Phase 2/3 Recruiting

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell